Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Stem Cell Transplantation"" wg kryterium: Temat

  Lista filtrów

Ogranicz do:

Wyrównaj
Wyświetlanie 1-25 z 122582
Tytuł:
Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Autorzy:
Tao Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Jin S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Yang D; Department of Hematology, Lu Daopei Hospital, 200025, Shanghai, China.
Pan M; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Ouyang W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Liu Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Wang Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
Zhang W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. .
Mi J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Apr 02; Vol. 24 (1), pp. 406. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Multiple Myeloma*/diagnosis
Hematopoietic Stem Cell Transplantation*
Humans ; Treatment Outcome ; Transplantation, Autologous ; Stem Cell Transplantation ; Chromosome Aberrations ; Neoplasm, Residual/diagnosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Autorzy:
Jia X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liao N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yu S; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Li H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liu H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Zhang H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Xu J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yao Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
He H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Yu G; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Zhang Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Shi P; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (4), pp. e7074.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/metabolism
Adult ; Humans ; Transplantation, Homologous ; Stem Cell Transplantation ; Recurrence ; Pathologic Complete Response ; Neoplasm, Residual ; Retrospective Studies ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Autorzy:
Guman T
Sykora J
Pokaż więcej
Źródło:
Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 125 (1), pp. 9-11.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chromosome Aberrations ; Disease Progression ; Disease-Free Survival ; Progression-Free Survival ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis.
Autorzy:
Alnasser SM; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Alharbi KS; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairy AF; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairi SM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Alolayan AM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Dec 18; Vol. 12 (24). Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/therapy
Immunoglobulin Light-chain Amyloidosis*/therapy
Lymphoma, Non-Hodgkin*/therapy
Humans ; Transplantation, Autologous ; Stem Cell Transplantation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stem Cell Therapy in Children with Traumatic Brain Injury.
Autorzy:
Lin WY; Department of Pediatrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Wu KH; Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Chen CY; Department of Emergency Medicine, Tung's Taichung MetroHarbor Hospital, Taichung 433, Taiwan.; Department of Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 79-9, Taiwan.
Guo BC; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Chang YJ; Laboratory of Epidemiology and Biostastics, Changhua Christian Hospital, Changhua 500, Taiwan.
Lee TA; Department of Emergency Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan.
Lin MJ; Division of Cardiology, Department of Medicine, Taichung Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, Taichung 427413, Taiwan.; Department of Medicine, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Wu HP; College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.; Department of Pediatrics, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 28; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Brain Injuries, Traumatic*/therapy
Mesenchymal Stem Cell Transplantation*
Humans ; Child ; Stem Cell Transplantation ; Cognition
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.
Autorzy:
Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Deng J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Mi L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Zhao L; Department of Lymphoma, Peking University International Hospital, Beijing, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10351-10362. Date of Electronic Publication: 2023 Apr 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease*/drug therapy
Humans ; East Asian People ; Neoplasm Recurrence, Local ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial.
Autorzy:
McCourt O; Therapies & Rehabilitation, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Haematology, UCL Cancer Institute, University College London, London, UK.
Fisher A; UCL Department of Behavioural Science and Health, University College London, London, UK.
Ramdharry G; Queens Square Centre for Neuromuscular Diseases, National Hospital for Neurology & Neurosurgery, UCLH NHS Trust/UCL Institute of Neurology, University College London, London, UK.
Land J; Department of Haematology, UCL Cancer Institute, University College London, London, UK.; UCL Department of Behavioural Science and Health, University College London, London, UK.
Roberts AL; UCL Department of Behavioural Science and Health, University College London, London, UK.
Rabin N; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Yong K; Department of Haematology, UCL Cancer Institute, University College London, London, UK.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Jul; Vol. 62 (7), pp. 696-705. Date of Electronic Publication: 2023 Feb 15.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Multiple Myeloma*/therapy
Hematopoietic Stem Cell Transplantation*/methods
COVID-19*/epidemiology
Humans ; Quality of Life ; Preoperative Exercise ; Hand Strength ; Pandemics ; Pilot Projects ; Transplantation, Autologous ; Stem Cell Transplantation ; Exercise ; Fatigue/etiology ; Exercise Therapy/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Autorzy:
Lin CM; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Otolaryngology, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan.
Chang LC; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shau WY; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen CL; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yao CY; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, 100225, Taiwan.
Tien FM; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. .; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, 100225, Taiwan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 May 16; Vol. 23 (1), pp. 446. Date of Electronic Publication: 2023 May 16.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Male ; Humans ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Disease-Free Survival ; Stem Cell Transplantation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.
Autorzy:
Zhou H; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Jian Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Du J; Department of Hematology, The Myeloma & Lymphoma Center, The Second Military Medical University, Shanghai, China.
Liu J; Department of Hematology, The First Affiliated Hospital to Sun Yat-sen University, Guangdong, Guangzhou, China.
Zhang Z; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Yang G; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Wang G; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Tian Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Li Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Wu Y; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Chen W; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Fu W; Department of Hematology, The Myeloma & Lymphoma Center, The Second Military Medical University, Shanghai, China.; Department of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Li J; Department of Hematology, The First Affiliated Hospital to Sun Yat-sen University, Guangdong, Guangzhou, China.
Gao W; Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Chaoyang, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9085-9096. Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Prognosis ; Nomograms ; Retrospective Studies ; Transplantation, Autologous ; Stem Cell Transplantation ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.
Autorzy:
Suzuki K; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Mizuno S; Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Shimazu Y; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Fuchida SI; Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Hagiwara S; Division of Hematology, Tsukuba University Hospital Mito Clinical Education and Training Center, Tsukuba, Japan.
Itagaki M; Department of Hematology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Nishiwaki K; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Hangaishi A; Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.
Karasuno T; Division of Hematology, Rinku General Medical Center, Izumisano, Japan.
Kikuchi T; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shimizu M; Department of Hematology and Oncology, Hitachi, Ltd. Hitachi General Hospital, Hitachi, Japan.
Nishikawa A; Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Kobayashi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Hiramoto N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Uchiyama H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Maruyama Y; Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kanda Y; Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Aichi, Japan.
Yano S; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan.
Kawamura K; Division of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.
Pokaż więcej
Corporate Authors:
Working Group of the Japan Society
for Transplantation and Cellular Therapy
Źródło:
European journal of haematology [Eur J Haematol] 2023 Apr; Vol. 110 (4), pp. 444-454. Date of Electronic Publication: 2023 Jan 17.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*
Humans ; Aged ; Retrospective Studies ; Transplantation, Autologous ; Stem Cell Transplantation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic Leukemia
Autorzy:
Ye P; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Lin Q; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Jin M; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Gu X; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Lu Y; The Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, Zhejiang, China
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Feb 28; Vol. 40 (1), pp. 73-74. Date of Electronic Publication: 2022 Dec 13.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Neutrophilic, Chronic*/genetics
Leukemia, Neutrophilic, Chronic*/therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Nitriles ; Stem Cell Transplantation ; Mutation ; Receptors, Colony-Stimulating Factor/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol.
Autorzy:
Dennett AM; School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia.; Allied Health Clinical Research Office, Eastern Health, Box Hill, Australia.
Porter J; Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Burwood, Australia.
Ting SB; Department of Clinical Haematology, Eastern Health, Box Hill, Australia.; Eastern Health Clinical School, Monash University, Box Hill, Australia.
Taylor NF; School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia.; Allied Health Clinical Research Office, Eastern Health, Box Hill, Australia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Apr 27; Vol. 18 (4), pp. e0277760. Date of Electronic Publication: 2023 Apr 27 (Print Publication: 2023).
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Humans ; Pilot Projects ; Quality of Life ; Preoperative Exercise ; Transplantation, Autologous ; Australia ; Stem Cell Transplantation ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study.
Autorzy:
Jung J; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.
Kim K; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Yoon SS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Lee JH; Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Kim JS; Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Shin HJ; Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Bang SM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Sohn SK; Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kong SY; Targeted Therapy Branch, Research Institute, National Cancer Center, Goyang, Korea.; Department of Laboratory Medicine, Hospital, National Cancer Center, Goyang, Korea.; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
Min CK; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eom HS; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.
Pokaż więcej
Corporate Authors:
Korean Multiple Myeloma Working Party; Center for Hematologic Malignancies, National Cancer Center, Goyang, Korea.
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Apr; Vol. 55 (2), pp. 693-703.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Bortezomib/adverse effects ; Dexamethasone/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation, Autologous ; Cyclophosphamide/adverse effects ; Stem Cell Transplantation/methods ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Autorzy:
Kaloyannidis P; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Zayer M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Darweesh M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Batran M; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Garni A; Department of Pathology & Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Naim A; Medical Imaging Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Al Hashmi H; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Kanfar S; Adult Hematology & Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 742-745. Date of Electronic Publication: 2023 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Hodgkin Disease*/drug therapy
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Immunoconjugates*/therapeutic use
Humans ; Brentuximab Vedotin ; Bendamustine Hydrochloride ; Salvage Therapy ; Neoplasm Recurrence, Local ; Transplantation, Autologous ; Stem Cell Transplantation ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
Autorzy:
Montoro MJ; Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Pomares H; ICO-Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Spain.
Coll R; ICO-Hospital Universitari Doctor Josep Trueta, Girona, Spain.
Bernal Del Castillo T; Hospital Universitario Central de Asturias, Oviedo, Spain.
Tormo M; Hospital Clínico Universitario de Valencia e Instituto de Investigación INCLIVA, Valencia, Spain.
Jiménez A; Hospital Universitario Ramón y Cajal, Madrid, Spain.
Brunet S; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Casaño J; Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain.
Oiartzabal I; Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
Díez-Campelo M; Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
Ramos F; Hospital Universitario de León, León, Spain.
Romero R; Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
Salido-Fiérrez E; Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, Murcia, Spain.
Pedro C; Hospital del Mar, Barcelona, Spain.
Bargay J; Hospital Son Llàtzer, Palma de Mallorca, Spain.
Muñoz-Novas C; Hospital Universitario Infanta Leonor, Madrid, Spain.
López R; Celgene S.L.U., a Bristol-Myers Squibb Company, Madrid, Spain.
Rafel M; Celgene S.L.U., a Bristol-Myers Squibb Company, Madrid, Spain.
Valcárcel D; Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain.
Pokaż więcej
Corporate Authors:
ERASME study group
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 679-690. Date of Electronic Publication: 2022 Dec 28.
Typ publikacji:
Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myelodysplastic Syndromes*/therapy
Myelodysplastic Syndromes*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Male ; Humans ; Aged ; Female ; Prospective Studies ; Treatment Outcome ; Stem Cell Transplantation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reduced cardiovascular reserve capacity in long-term allogeneic stem cell transplant survivors.
Autorzy:
Dillon HT; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Foulkes S; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.; University of Melbourne, Melbourne, Australia.
Horne-Okano YA; Baker Heart and Diabetes Institute, Melbourne, Australia.
Kliman D; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia.
Dunstan DW; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Daly RM; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Fraser SF; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.
Avery S; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia.
Kingwell BA; Baker Heart and Diabetes Institute, Melbourne, Australia.; CSL Ltd, Melbourne, Australia.
La Gerche A; Baker Heart and Diabetes Institute, Melbourne, Australia.; University of Melbourne, Melbourne, Australia.; Cardiology Department, St Vincent's Hospital Melbourne, Fitzroy, Australia.
Howden EJ; Baker Heart and Diabetes Institute, Melbourne, Australia. .; University of Melbourne, Melbourne, Australia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Feb 06; Vol. 13 (1), pp. 2112. Date of Electronic Publication: 2023 Feb 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ventricular Function, Left*
Hematopoietic Stem Cell Transplantation*
Male ; Humans ; Female ; Stroke Volume ; Survivors ; Exercise Test/methods ; Stem Cell Transplantation ; Oxygen Consumption
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Autorzy:
Kumar L; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sahoo RK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Baa AK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Tansir G; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Pathak N; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Malik PS; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma OD; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Mathew A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Jha A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Gupta R; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Biswas A; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar R; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Thulkar S; Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, India.
Malik S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Dutt A; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Pokaż więcej
Corporate Authors:
for AIIMS Myeloma Group
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 378-387. Date of Electronic Publication: 2022 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Melphalan/adverse effects ; Transplantation, Autologous ; Neoplasm Recurrence, Local/drug therapy ; Stem Cell Transplantation ; Treatment Outcome ; Transplantation Conditioning/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microdrilling combined with high tibial osteotomy for cartilage regeneration.
Autorzy:
Jung SH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Nam BJ; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Choi CH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim S; Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung M; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chung K; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
Park J; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.
Jung Y; Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim SH; Arthroscopy and Joint Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. .; Department of Orthopedic Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 09; Vol. 14 (1), pp. 3333. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Cartilage, Articular*/surgery
Cartilage, Articular*/pathology
Osteoarthritis, Knee*/surgery
Osteoarthritis, Knee*/pathology
Mesenchymal Stem Cells*
Hematopoietic Stem Cell Transplantation*
Mesenchymal Stem Cell Transplantation*
Humans ; Fetal Blood ; Second-Look Surgery ; Osteotomy ; Regeneration
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mucosal microbiotas and their role in stem cell transplantation.
Autorzy:
Ingham AC; Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Pamp SJ; Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Pokaż więcej
Źródło:
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2022 Dec; Vol. 130 (12), pp. 741-750. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*/microbiology
Microbiota*
Humans ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Stem Cell Transplantation/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
Autorzy:
Mikulski D; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.
Kościelny K; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Nowicki M; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Wawrzyniak E; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Kalwas M; Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
Kowalik M; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.
Pryt M; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Sęczkowska E; Department of Anesthesiology and Intensive Medical Therapy, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Świątek A; Department of Internal Medicine and Gastroenterology, Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland.
Wierzbowska A; Department of Hematology, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland.; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Fendler W; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.; Department of Radiation Oncology, Dana‑Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 98-106. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Progression-Free Survival ; Neutrophils ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation, Autologous ; Lymphocytes ; Stem Cell Transplantation ; Disease-Free Survival ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
Autorzy:
Geng C; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Zhou H; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Wang H; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Li Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Leng Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Zhang Z; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Jian Y; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Yang G; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. .
Chen W; Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Dec 23; Vol. 22 (1), pp. 1349. Date of Electronic Publication: 2022 Dec 23.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/diagnosis
Humans ; Aged ; Retrospective Studies ; Transplantation, Autologous ; Prognosis ; Stem Cell Transplantation ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Autorzy:
Zhang L; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; First Affiliated Hospital of Soochow University, Department of Ultrasound, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Yang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Qian C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Zhou J; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China.
Zhu Q; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Jiang Y; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Liu S; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Chen X; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Xu T; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Qu C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Li C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Jin Z; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.
Chu J; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.
Zhang X; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China.
Wu D; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.
Huang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 404-411.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma*/therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Etoposide/adverse effects ; Humans ; Melphalan/adverse effects ; Retrospective Studies ; Semustine ; Stem Cell Transplantation ; Transplantation Conditioning/adverse effects ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Autorzy:
Taranto E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeter E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
McHugh K; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Crombie JL; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Fisher DC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacobsen E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacobson CA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Kim AI; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
LaCasce AS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Odejide OO; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nieto Y; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joyce RM; Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chen YB; Hematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Bonjoc KC; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Chaudhry A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Merryman RW; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2912-2917. Date of Electronic Publication: 2022 Aug 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Hodgkin Disease*/diagnosis
Hodgkin Disease*/therapy
Hodgkin Disease*/pathology
Humans ; Transplantation, Autologous ; Prognosis ; Neoplasm, Residual/diagnosis ; Leukocytes, Mononuclear/pathology ; Neoplasm Recurrence, Local ; Stem Cell Transplantation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Autorzy:
Song GY; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Kim HJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Kim T; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.; Department of Computer Science, University of Toronto, Toronto, ON, Canada.; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada.
Ahn SY; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Kim M; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Yang DH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Lee JJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.
Kim MY; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Gwangju, Jeollanam-Do, Republic of Korea.
Cheong JW; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung CW; Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea.
Jang JH; Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea.
Kim HJ; Department of Hematology, The Catholic University of Korea, Seoul, South Korea.
Moon JH; Department of Hematology-Oncology, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea.
Sohn SK; Department of Hematology-Oncology, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea.
Won JH; Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
Park SK; Division of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
Kim SH; Department of Hematology-Oncology, Dong-A University College of Medicine, Busan, South Korea.
Choi CK; Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Canter, Goyang, South Korea.
Kim HJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea.; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Gwangju, Jeollanam-Do, Republic of Korea.
Ahn JS; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Jeollanam-Do, Republic of Korea. .; Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Gwangju, Jeollanam-Do, Republic of Korea. .; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University, 322 Seoyang-Ro, Hwasun-Eup, Hwasun-Gun, Jeollanam-Do, 58128, Republic of Korea. .
Kim DDH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 12; Vol. 14 (1), pp. 8517. Date of Electronic Publication: 2024 Apr 12.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Humans ; Genetic Profile ; Risk Assessment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Autorzy:
Kim DDH; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Popradi G; Health Centre, McGill University, Montreal, QC H4P 2P5, Canada.
Lepic K; Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Paulson K; CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, MB R3E 0V9, Canada.
Allan D; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Nampoothiri RV; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Lachance S; Hôpital Maisonneuve-Rosemont, Department of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.
Deotare U; London Health Sciences Centre, University of Western Ontario, London, ON N6A 5A5, Canada.
White J; Vancouver General Hospital, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Elemary M; Saskatchewan Cancer Agency, University of Saskatchewan, Saskatchewan, SK S7N 4H4, Canada.
Jamani K; Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, Canada.
Fraga C; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Lemieux C; CHU de Québec-Université Laval, Université Laval, Québec, QC G1R 2J6, Canada.
Novitzky-Basso I; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Law AD; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Kumar R; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Walker I; Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Schultz KR; British Columbia Children's Hospital, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Pokaż więcej
Corporate Authors:
CTTC Chronic GVHD Guideline Working Group
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Mar 08; Vol. 31 (3), pp. 1426-1444. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Guideline
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Bronchiolitis Obliterans Syndrome*
Graft vs Host Disease*/drug therapy
Graft vs Host Disease*/etiology
Graft vs Host Disease*/pathology
Adult ; Humans ; Child ; Consensus ; Chronic Disease ; Canada
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-25 z 122582

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies